Previous 10 | Next 10 |
Invaio Sciences Announces Key Agreement with Fundecitrus in Brazil to Combat Against Citrus Greening PR Newswire CAMBRIDGE, Mass. , May 19, 2021 /PRNewswire/ -- Invaio Sciences, Inc., a Flagship Pioneering company focused on unlocking the potential of the planet'...
Shares of Evelo Biosciences (EVLO) shot up 7% in morning trading after the company announced positive preclinical data on EDP2939 for inflammatory diseases.EDP2939, an extracellular vesicle candidate, showed broad- resolution of inflammation in mouse models, with no safety or tolera...
–On-track to initiate clinical development of EDP2939 in 2022– CAMBRIDGE, Mass., May 13, 2021 (GLOBE NEWSWIRE) -- Evelo Biosciences, Inc. (Nasdaq:EVLO), a clinical stage biotechnology company developing a new modality of orally delivered medicines, today presented pr...
Gainers: Precipio (PRPO) +102%.Regional Health Properties (RHE) +94%.American Shared Hospital Services (AMS) +33%.Brooklyn ImmunoTherapeutics (BTX) +26%.Scully Royalty (SRL) +25%.Ocugen (OCGN) +23%.Top Ships (TOPS) +23%.Rezolute (RZLT) +20%.Milestone Scientific (MLSS) +19%.Ashford H...
Gainers: Regional Health Properties (RHE) +92%, Brooklyn ImmunoTherapeutics (BTX) +32%, Precipio PRPO +30%, Rezolute (RZLT) +28%, Milestone Scientific (MLSS) +15%.Losers: Vaxart VXRT -18%, Regulus Therapeutics RGLS -18%, Humanigen (HGEN)&...
Evelo Biosciences, Inc (EVLO) Q1 2021 Earnings Conference Call April 29, 2021 8:30 AM ET Company Participants Jessica Cotrone – Vice President Simba Gill – Chief Executive Officer Mark Bodmer – President of R&D and Chief Scientific Officer Jonathan Zung – Chief...
Image source: The Motley Fool. Evelo Biosciences, Inc. (NASDAQ: EVLO) Q1 2021 Earnings Call Apr 29, 2021 , 8:30 a.m. ET Operator Continue reading For further details see: Evelo Biosciences, Inc. (EVLO) Q1 2021 Earnings Call Transcript
Evelo Biosciences (EVLO): Q1 GAAP EPS of -$0.55 misses by $0.03.As of March 31, 2021, cash and cash equivalents were $124.6 million, as compared to cash and cash equivalents of $68.9 million as of December 31, 2020.Press Release For further details see: Evelo Biosciences EPS misses by $...
–Presented further positive data from Phase 1b clinical trial of EDP1815 at International Society of Atopic Dermatitis Meeting– –Strengthened leadership team with appointments of Luca Scavo as Chief Financial Officer and Julie H. McHugh to Board of Directors– ...
Warning signals are flashing, suggesting it could be smart to fade the next move up. The strongest sectors currently include financials, REITs, and consumer goods. Over 100 highly-rated stocks across every major sector for your watch lists. For further details see: One L...
News, Short Squeeze, Breakout and More Instantly...
Evelo Biosciences Inc. Company Name:
EVLO Stock Symbol:
OTCMKTS Market:
Evelo Biosciences Inc. Website:
ADDvantage Technologies Group Inc. (AEYGQ) is expected to report for Q1 2024 ContraFect Corporation (CFRXQ) is expected to report for Q1 2024 American Clean Resources Group Inc (ACRG) is expected to report for Q1 2024 Atlantic Lithium Ltd Ord Fully Paid (ALLIF) is expected to report f...
Windtree Therapeutics Inc. (WINT) is expected to report for Q1 2024 CohBar Inc. (CWBR) is expected to report for Q1 2024 hopTo Inc (HPTO) is expected to report for Q1 2024 Bitech Technologies Corporation (BTTC) is expected to report for Q1 2024 Roadzen Inc. (RDZN) is expected to r...
Gelesis Holdings, Inc. (GLSHQ) is expected to report for Q1 2024 EVmo Inc (YAYO) is expected to report for Q1 2024 Chiba Bank Ltd. ADR (CHBAY) is expected to report for Q4 2024 Spark Networks SE (LOVLQ) is expected to report for Q1 2024 ToughBuilt Industries Inc. (TBLT) is expecte...